Letter
Oncology
Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi, Masahito Shimizu
Summary: This study aimed to evaluate the efficacy and safety of BRAC combination therapy in patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma. The results showed that BRAC therapy had a good response rate but also caused significant hematological toxicity.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Rouslan Kotchetkov, Ian R. Drennan, David Susman, Erica DiMaria, Lauren Gerard, Derek Nay, Anca Prica
Summary: This study compared the safety and efficacy of BR therapy in elderly and younger patients. The results showed that elderly patients were more likely to experience treatment delays and dose reductions, but the disease control outcome was similar between the two groups.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Kayoko Murayama, Toru Kiguchi, Koji Izutsu, Yoshihiro Kameoka, Michihiro Hidaka, Harumi Kato, Shinya Rai, Junya Kuroda, Kenichi Ishizawa, Satoshi Ichikawa, Kiyoshi Ando, Michinori Ogura, Koji Fukushima, Yasuhito Terui
Summary: This study aimed to confirm the effectiveness and tolerability of bendamustine-rituximab combination therapy in patients with relapsed/refractory diffuse large B cell lymphoma. The results showed that the combination therapy was effective in achieving disease response and was well tolerated, with an overall response rate of 76.3% in the patients.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu
Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.
Review
Hematology
Toby A. Eyre, Chan Y. Cheah, Michael L. Wang
Summary: This review discusses the key therapeutic approaches in the management of relapsed mantle cell lymphoma (MCL), with a focus on the use of covalent Bruton tyrosine kinase (BTK) inhibitors. The review also explores treatment options after BTK inhibitor therapy, including chimeric antigen receptor T-cell therapy and novel therapies.
Review
Immunology
Jinjin Wang, Hui Zhou, Mingchun Mu, Ailin Zhao, Zhaolun Cai, Linfeng Li, Mengyao Wang, Ting Niu
Summary: This meta-analysis evaluated the efficacy and safety of Copanlisib in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). The results showed that both Copanlisib monotherapy and combination therapy with rituximab were effective in R/R B-NHL patients, with manageable treatment-related adverse events.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Health Care Sciences & Services
Madelyn Burkart, Reem Karmali
Summary: Mantle cell lymphoma (MCL) is a rare and challenging B-cell non-Hodgkin lymphoma. Current therapies aim to palliate and prolong survival, but resistance becomes a problem. Agents like Bruton's tyrosine kinase inhibitors (BTKi) have improved outcomes, but resistance to BTKi is an issue.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Hematology
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Summary: The study demonstrates favorable outcomes for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma treated with the selective Bruton's tyrosine kinase inhibitor zanubrutinib. The results support zanubrutinib as a potentially meaningful addition to available therapies for these patients.
Article
Biochemistry & Molecular Biology
Lihua E. Budde, Adam J. Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D. Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Julio C. Chavez
Summary: In an ongoing phase 1/2 trial, the combination of mosunetuzumab and polatuzumab vedotin showed a promising overall response rate of 59.2% for second-line treatment in patients with transplant-ineligible or CAR-T-cell-ineligible relapsed or refractory large B cell lymphoma.
Article
Hematology
Mehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, Olga Meltem Akay, Sevgi Besisik, Mustafa Nuri Yenerel, Serhat Celik, Leylagul Kaynar, Orhan Kemal Yucel, Burak Deveci, Mehmet Sonmez, Ozgur Mehtap, Huseyin Saffet Bekoz, Cenk Sunu, Ozan Salim, Turgay Ulas, Sami Karti, Fevzi Altuntas, Burhan Ferhanoglu, Tulin Firat Tuglular
Summary: Through analyzing the data of 71 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) treated with Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) from March 2018 to April 2021, it was found that Pola-BR is a promising option with an overall response rate of 47.9% and a complete response rate of 32.4% after a median of 3 cycles. The median overall survival was 5 months with manageable hematological toxicities of grade 3-4 neutropenia and thrombocytopenia.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss, Pier Luigi Zinzani
Summary: Umbralisib demonstrated meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yuan-Kai Shi, Xiao-Nan Hong, Jian-Liang Yang, Wei Xu, Hui-Qiang Huang, Xiu-Bin Xiao, Jun Zhu, Dao-Bin Zhou, Xiao-Hong Han, Jian-Qiu Wu, Ming-Zhi Zhang, Jie Jin, Xiao-Yan Ke, Wei Li, De-Pei Wu, Shen-Miao Yang, Xin Du, Yong-Qian Jia, Ai-Chun Liu, Dai-Hong Liu, Zhi-Xiang Shen, Lian-Sheng Zhang, Leonard James, Edward Hellriegel
Summary: The study demonstrated the efficacy and safety of bendamustine in Chinese patients with relapsed, indolent B-cell NHL, with a high ORR of 73% and consistent pharmacokinetic characteristics with other ethnicities.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Yasuhito Terui, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Hirohiko Shibayama
Summary: The study demonstrated the efficacy and safety of the combination of Polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma who were ineligible for autologous stem cell transplantation.
Article
Multidisciplinary Sciences
Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Daehun Kwag, Byung-Su Kim, Joonyeop Lee, Jong Hyuk Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho
Summary: In this study, we analyzed the clinical characteristics and outcomes of 52 patients with relapsed/refractory diffuse large B cell lymphoma treated with allo-HSCT. Overall survival, event-free survival, and graft-versus-host disease-free, relapse-free survival outcomes were significantly better in patients who achieved remission before allo-HSCT. A shorter interval from diagnosis to allo-HSCT was associated with poorer survival and higher relapse rates. Patients with active disease had lower event-free survival and graft-versus-host disease-free, relapse-free survival.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Yoshinori Hashimoto, Tomoki Ito, Yasuhiro Tanaka, Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Akiko Konishi, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Akiko Hashimoto, Toshinori Kondo, Hiromi Omura, Isaku Shinzato, Takayuki Tanaka, Shosaku Nomura
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2020)
Article
Hematology
Atsushi Satake, Akiko Konishi, Yoshiko Azuma, Yukie Tsubokura, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura
EUROPEAN JOURNAL OF HAEMATOLOGY
(2020)
Article
Hematology
Aya Nakaya, Hirokazu Tanaka, Hideo Yagi, Kensuke Ohta, Hirohiko Shibayama, Takae Kohara, Junya Kanda, Maki Shindo, Yuji Shimura, Satoru Kosugi, Toru Kida, Hitomi Kaneko, Kazunori Imada, Takahiro Karasuno, Mitsuhiro Matsuda, Masato Iida, Yoko Adachi, Shin-ichi Fuchida, Nobuhiko Uoshima, Hitoji Uchiyama, Ryoichi Takahashi, Toshimitsu Matsui, Katsuya Wada, Miki Kiyota, Chihiro Shimazaki, Masayuki Hino, Junya Kuroda, Yuzuru Kanakura, Akifumi Takaori-Kondo, Shosaku Nomura, Itaru Matsumura
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2020)
Article
Hematology
Teruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Aya Nakaya, Shin-ichi Fuchida, Hirohiko Shibayama, Mitsuhiro Matsuda, Yutaka Shimazu, Yoko Adachi, Satoru Kosugi, Hitoji Uchiyama, Hirokazu Tanaka, Hitoshi Hanamoto, Yuji Shimura, Junya Kanda, Yoshiyuki Onda, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Summary: The study investigated real-world data of IRd therapy for RRMM patients, with a median age of 72 and most patients having IgG type. The median number of prior therapies was 4, mainly comprising bortezomib and lenalidomide-based regimens. Disease progression and adverse events were common reasons for treatment discontinuation. The study found that lenalidomide-refractory patients had significantly lower PFS than lenalidomide-sensitive patients, and the patients with IgG type had significantly better PFS and OS. Overall, IRd showed poor efficacy in non-IgG type and lenalidomide-refractory patients with RRMM in real clinical practice.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Makoto Osada, Keiko Maruyama, Koichi Kokame, Ryunosuke Denda, Kohei Yamazaki, Hisako Kunieda, Maki Hirao, Seiji Madoiwa, Nobuo Okumura, Mitsuru Murata, Yasuo Ikeda, Kentaro Watanabe, Yuiko Tsukada, Takahide Kikuchi
Summary: A 19-year-old Vietnamese woman experienced life-threatening bleeding events, which were not corrected by hemostatic surgery and medications, but remarkably improved with recombinant human thrombomodulin. A novel homozygous variation in the TM gene was identified through screening and sequencing, possibly leading to reduced TM expression on endothelial cell membrane. This reduced expression may explain the disseminated intravascular-coagulation-like symptoms observed in the patient.
Editorial Material
Microbiology
Aroonsiri Sangarlangkarn, Yuji Yamada, Fred C. Ko
Summary: With the increasing life expectancy of HIV patients and the emergence of multiple geriatric syndromes, HIV clinicians face challenges in providing care for older adults living with HIV. Current HIV guidelines have limitations in addressing the multifactorial conditions, patient-centered outcomes, representation in clinical trials, and criteria for inclusion for older HIV patients. Strategies such as using baseline attributes, time to benefit, and the Geriatrics 5M model can aid in shared decision making and improving outcomes for older HIV patients while waiting for updated guidelines to be developed.
Editorial Material
Oncology
Aya Nakaya, Kazuyoshi Ishii, Shosaku Nomura
HEMATOLOGY TRANSFUSION AND CELL THERAPY
(2021)
Review
Immunology
Yuji Yamada, Takaaki Kobayashi, Angela Condo, Aroonsiri Sangarlangkarn, Fred Ko, Yu Taniguchi, Gotaro Kojima
Summary: The systematic review identified a variation in frailty prevalence among individuals aged 50 or older with HIV. The meta-analysis results showed that the overall prevalence of frailty and prefrailty in this population was 10.9% and 47.2% respectively. Frailty is a clinically recognized state associated with disability, hospitalization, and mortality. Effective strategies for frailty screening and intervention are needed for this vulnerable population.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Immunology
Takaaki Kobayashi, Yuka Nishina, Hana Tomoi, Ko Harada, Kyuto Tanaka, Eiyu Matsumoto, Kenta Horimukai, Jun Ishihara, Shugo Sasaki, Kanako Inaba, Kyosuke Seguchi, Hiromizu Takahashi, Jorge L. Salinas, Yuji Yamada
Summary: A study found that the use of mobile messenger apps can reduce vaccine hesitancy among users. The survey results showed that vaccine hesitancy decreased from 41% to 20% after using Corowa-kun. Factors such as age, gender, and previous vaccine side effects were found to be associated with vaccine hesitancy.
Article
Medicine, General & Internal
Hisako Kunieda, Ryunosuke Denda, Kohei Yamazaki, Maki Hirao, Yuiko Tsukada, Yu Iwabuchi, Eisuke Shiomi, Shigeru Watanabe, Shinichiro Okamoto, Takahide Kikuchi
Summary: A case of Philadelphia chromosome-positive acute lymphoblastic leukemia was incidentally detected by F-18-FDG PET/CT, even though other physical examination and blood test results were normal. Physicians should be cautious of potential hematological malignancies even when diffuse bone marrow uptake of F-18-FDG is the only abnormal finding.
Review
Pediatrics
Atsuyuki Watanabe, Jun Yasuhara, Masao Iwagami, Yoshihisa Miyamoto, Yuji Yamada, Yukio Suzuki, Hisato Takagi, Toshiki Kuno
Summary: This study investigated the association between COVID-19 vaccination during pregnancy and peripartum outcomes. The study found that COVID-19 vaccination during pregnancy was associated with a lower risk of NICU admission and intrauterine fetal death. Additionally, it was also associated with a decreased risk of maternal SARS-CoV-2 infection. However, there was no significant association between COVID-19 vaccination during pregnancy and preterm birth, small for gestational age, and low Apgar score.
Article
Hematology
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda
Summary: This retrospective analysis evaluated the real-world survival benefits and safety profiles of KRd and Kd therapies. The results showed that the reduction of carfilzomib dose and refractoriness to prior treatments were associated with lower survival rates. Adverse events were common in both therapies.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Infectious Diseases
Aya Nakaya, Eiji Ogura, Yuki Katayama, Masami Yoshii, Eiko Yoshino, Kazuya Hozumi, Saori Tago, Yuko Teranishi, Yuki Minamibashi, Makiko Harada, Mami Yoshioka, Yuri Kawano, Yuka Arai, Keno Yoshida, Shozo Shimizu, Kazuma Ogura, Katsuaki Iwashita
Summary: It has been reported that hiccups may be a specific neurological symptom in male COVID-19 patients, occurring in 11% of the cases analyzed. These patients usually do not experience dysgeusia or anosmia.
Article
Infectious Diseases
Aya Nakaya, Eiji Ogura, Yuki Katayama, Masami Yoshii, Eiko Yoshino, Kazuya Hozumi, Saori Tago, Yuko Teranishi, Yuki Minamibashi, Makiko Harada, Mami Yoshioka, Yuri Kawano, Yuka Arai, Keno Yoshida, Shozo Shimizu, Kazuma Ogura, Katsuaki Iwashita
Summary: The study found that the red face in patients with COVID-19 variants may indicate a cytokine storm and predict a sudden deterioration in their condition.
Article
Hematology
Aya Nakaya, Huiying Qiu, Erlinda B. Santos, Donald K. Hamlin, D. Scott Wilbur, Rainer Storb, Brenda M. Sandmaier
Summary: In a canine model, the combination of At-211-anti-CD45 mAb with TBI successfully prevented graft rejection in 86% of dogs, demonstrating a promising strategy to overcome rejection in heavily transfused patients with red cell disorders.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)